The effectiveness and cost-effectiveness of implementing evidence-based depression treatment within the TB care platform in south africa: a hybrid effectiveness-implementation trial
Active Project Grant Awarded Last action
- Award ID
- R01AI148461
- Recipient
-
Research Foundation For Mental Hygiene, Inc. UEI TYVNMW8FNQQ3 Part of Research Foundation For Mental Hygiene Inc.
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,198,968
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 74% complete
- Originally
- Funding
-
- $5,585,592.00 Federal
- $613,376.00 Non-federal
- Place of performance
- New York, NY 10032, USA
Award details come from USAspending.gov.
Description
- Abstract
- TB and major depressive disorder (MDD) are the leading infectious cause of death and the leading cause of disability, respectively. Furthermore, they are commonly CO-occurring and negatively synergistic. TB and MDD comorbidity is associated with a 2.85 greater chance of death and 8.70 higher risk for loss to follow up (LTFU) from treatment, which has a cascade of negative individual-, community-, societal-, and health system-level implications. As a treatable condition, MDD is a remediable driver of the TB epidemic. The who has called for a global policy framework for TB and mental health integration, recommending brief psychological interventions to address mental disorders in primary care settings. Interpersonal counseling (IPC) is a brief version of one such evidence-based intervention that has demonstrated efficacy and effectiveness in treating MDD when delivered by non-mental health specialists, including in south africa. The purpose of this study is to assess the effectiveness and cost-effectiveness of integrating IPC (for MDD) into the TB care platform to improve TB and MD outcomes, as well as mitigate TB-related catastrophic costs. As the country with the highest TB burden in the world, nearly 60% of whom are CO-infected with HIV, south africa is the ideal setting for this study. We propose a 3-year hybrid type I effectiveness-implementation trial in eight clinics (N~1410 individuals with TB/MDD) in the eastern cape of south africa to integrate IPC to treat MDD comorbidity within the TB care platform with the following aims: aim 1: to evaluate the effectiveness and implementation outcomes of integrating IPC treatment for MDD into the existing TB care platform to improve TB and MDD outcomes aim 2: to determine the influence of theoretically based intervention mediators and moderators on TB treatment outcomes aim 3: to assess the cost-effectiveness of integrating MDD treatment into the TB care platform from the patient and health system perspectives our team will be led by an early-stage investigator who is a global expert in TB and MDD, supported by senior investigators with extensive experience conducting TB and MH-related effectiveness, cost-effectiveness, and hybrid trials (including in south africa). This research will provide critical clinical, programmatic, and economic data to inform the who global policy framework for TB and mental health integration, and cost-effective clinical practice to improve TB outcomes, especially in low-resource settings.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $32,236 | $0 | |
| Amendment | $344,192 | $0 | |
| Amendment | $344,192 | $0 | |
| Amendment | $32,236 | $0 | |
| Amendment | $197,850 | $0 | |
| Amendment | $197,850 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $71,881 | $0 | |
| Amendment | $71,881 | $0 | |
| Amendment | $71,881 | $0 | |
| Amendment | $71,881 | $0 | |
| Amendment | $584,552 | $0 | |
| Amendment | $584,552 | $0 | |
| Amendment | $584,552 | $0 | |
| Amendment | $584,552 | $0 | |
| Amendment | $584,552 | $0 | |
| Amendment | $613,376 | $0 | |
| Original award | $613,376 | $613,376 |
Show all 30
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Desmond Tutu Health Foundation | $344,192 | |
| Desmond Tutu Health Foundation | $358,324 |
Quick answers
Who received award R01AI148461?
R01AI148461 was awarded to Research Foundation For Mental Hygiene, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 23, 2021.
How much is award R01AI148461 worth?
$6,198,968 has been obligated on R01AI148461: $5,585,592 in federal funding and $613,376 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award